Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The ADMIRAL (Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute
myocardial infarction) study demonstrated that early administration of abciximab in patients
with ST elevation acute myocardial infarction prior to PCI improves clinical outcomes but no
specifically designed randomized study has addressed the issue of early upstream use of GP
IIb/IIIa inhibitors in ST elevation acute myocardial infarction who are undergoing PCI,
especially in the era of routine pretreatment with 600 mg of clopidogrel. Therefore, the
objective of the randomized ECLAT-STEMI study was to assess the hypothesis that the early
upstream use of Clotinab is a useful therapy in patients with ST elevation MI undergoing PCI
compared to "provisional use", even after pretreatment with a 600-mg loading dose of
clopidogrel.
Phase:
Phase 4
Details
Lead Sponsor:
Yonsei University
Collaborator:
ISU ABXIS (Korea pharmaceutical company)
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments